Skip to main content

Table 6 Surgical results and overall response

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

 

Dose level

 
 

1

2

3

Total

Number of patients

4 (100%)

13 (100%)

7 (100%)

24 (100%)

Surgery?

    

  No

1 (25%)

2 (15%)

3 (43%)

6 (25%)

  Yes

3 (75%)

11 (85%)

4 (57%)

18 (75%)

If so:

    

  R0

2 (67%)

8 (73%)

4 (100%)

14 (78%)

Grading

    

  G2

 

3 (27%)

1 (25%)

4 (22%)

  G3

2 (67%)

4 (36%)

2 (50%)

8 (44%)

  Information missing

1 (33%)

4 (36%)

1 (25%)

6 (33%)

Response prior to surgery (RECIST)

    

  N

3 (100%)

12 (100%)

7 (100%)

22 (100%)

  PR

2 (67%)

3 (25%)

2 (29%)

7 (32%)

  SD

 

5 (42%)

2 (29%)

7 (32%)

  PD

1 (33%)

2 (17%)

2 (29%)

1 (5%)

  NK/ND

 

2 (17%)

1 (14%)

2 (9%)

Staging prior to surgery (UICC)

    

  N

4 (100%)

12 (100%)

7 (100%)

23 (100%)

  II A

 

4 (33%)

1 (14%)

5 (229%)

  II B

 

1 (8%)

1 (14%)

2 (9%)

  III

3 (75%)

4 (33%)

2 (29%)

9 (39%)

  IV

  

1 (14%)

1 (4%)

  NK/ND

1 (25%)

3 (25%)

2 (29%)

6 (26%)

Pathologic response [15]

    

  N

3 (100%)

11 (100%)

4 (100%)

18 (100%)

  CR

 

4 (36%)

2 (50%)

6 (33%)

  PR

1 (33%)

4 (36%)

2 (50%)

7 (39%)

  SD

 

1 (9%)

 

1 (6%)

  PD

1 (33%)

1 (9%)

 

2 (11%)

  NK/ND

1 (33%)

1 (9%)

 

2 (11%)

Staging after surgery (UICC)

    

  N

3 (100%)

11 (100%)

4 (100%)

18 (100%)

  0

 

2 (18%)

1 (25%)

3 (17%)

  I

 

1 (9%)

1 (25%)

2 (11%)

  II A

1 (33%)

2 (18%)

 

3 (17%)

  II B

1 (33%)

2 (18%)

2 (50%)

5 (28%)

  III

 

1 (9%)

 

1 (6%)

  NK/ND

1 (33%)

3 (27%)

 

4 (22%)